A small subset of people with neuromyelitis optica spectrum disorder (NMOSD) do not accumulate significant functional disability in the 15 years following symptom onset, according to a recent study. Called benign NMOSD, these patients were more likely to be Caucasian, less likely to have spinal cord involvement at disease…
News
SPHERES, a real-world registry for neuromyelitis optica spectrum disorder (NMOSD), is now collecting biological samples from consenting participants. Launched by CorEvitas and the Guthy-Jackson Charitable Foundation (GJCF) in 2021, the registry had been collecting long-term clinical data, but not biological samples. “The launch of this biospecimen…
Ultomiris (ravulizumab) has been approved by the European Commission to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4). “Effective NMOSD management hinges on reducing relapses – even a single relapse may cause irreversible disabilities leaving patients unable to move, speak…
High-efficacy treatments for neuromyelitis optica spectrum disorder (NMOSD) are associated with significant reductions in hospitalizations, relapses, and MRI lesions relative to traditional therapies, according to a recent study. The findings, which were published in the Journal of Neurology, were discussed in an oral presentation at the American…
Antibodies against aquaporin-4 (AQP4) are detectable in the blood several years before symptoms occur in most people with neuromyelitis optica spectrum disorder (NMOSD), according to a U.S. study. Tammy Smith, MD, PhD, of the University of Utah, presented the findings at the recent American Academy of Neurology (AAN) annual…
Up to 4.6 years of treatment with Enspryng (satralizumab) continues to safely reduce relapse rates and prevent disability progression for people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). That’s according to pooled data from the Phase 3 SAkuraSky (NCT02028884) and…
Experts in Germany have published recommendations to help clinicians diagnose neuromyelitis optica spectrum disorder (NMOSD) and distinguish it from other disorders with similar symptoms. The guidelines were detailed in “Update on the diagnosis and treatment of [neuromyelitis] optica spectrum disorders (NMOSD) – revised recommendations of the…
Plasma exchange, a blood-cleaning procedure, is safe and helps to ease symptoms in elderly people with neuromyelitis optica spectrum disorder (NMOSD), despite the presence of other health conditions. That finding is from a Chinese study that assessed the safety and efficacy of plasma exchange in elderly NMOSD patients (older…
SPHERES, a real-world registry designed to better understand neuromyelitis optica spectrum disorder (NMOSD) — its underlying mechanisms, clinical course, and treatment effects — has reached a milestone of 200 enrolled patients. Standing for Synergy of Prospective Health & Experimental Research for Emerging Solutions in NMOSD, the SPHERES…
Familial clustering of neuromyelitis optica spectrum disorders (NMOSD) — having more cases within families than what would be expected — is more common than originally thought. That’s according to a new study whose findings highlight a complex genetic predisposition to the progressive autoimmune disease. Certain DNA variants were shared…
Recent Posts
- Estrogen may drive brain inflammation in NMOSD: Mouse study
- I may have the dragon fruit of diseases, but let’s not compare apples to oranges
- 17-year-old advocate shares her NMOSD story to raise awareness
- Brain, nerve damage link to relapse, disability in AQP4-related NMOSD
- With NMOSD, my to-do lists now include staying well, as well as staying busy